Circassia Inks $98M For Biopharma
Oxford-based Circassia Ltd. has closed on 60 million pounds ($98 million) in new financing, bringing the total raised by the company to $159 million. The company, a specialty biopharmaceutical company focused on allergy treatments, will pull the money down in two tranches over the next two years. The money will fund phase three development of Circassia's cat and ragweed allergy therapies. Imperial Innovations led the round, which included investments from existing shareholders including Invesco Perpetual.
19 April 2011•3 mins read
